Sisomicin
Sisomicin[edit | edit source]
Sisomicin is an aminoglycoside antibiotic that is derived from the bacterium Micromonospora inyoensis. It is closely related to other aminoglycosides such as gentamicin and netilmicin. Sisomicin is primarily used in the treatment of serious bacterial infections caused by Gram-negative bacteria.
Mechanism of Action[edit | edit source]
Sisomicin, like other aminoglycosides, works by binding to the 30S ribosomal subunit of the bacterial ribosome. This binding interferes with the initiation complex of protein synthesis, leading to the misreading of mRNA and the production of nonfunctional or toxic peptides. The disruption of protein synthesis ultimately results in bacterial cell death, making sisomicin a bactericidal agent.
Clinical Uses[edit | edit source]
Sisomicin is used to treat a variety of infections, including:
- Urinary tract infections
- Respiratory tract infections
- Skin and soft tissue infections
- Intra-abdominal infections
It is particularly effective against Pseudomonas aeruginosa, Escherichia coli, and Klebsiella pneumoniae.
Administration and Dosage[edit | edit source]
Sisomicin is typically administered via intravenous or intramuscular injection. The dosage depends on the severity of the infection, the patient's renal function, and the susceptibility of the causative organism. It is important to monitor renal function and serum drug levels during treatment to avoid nephrotoxicity and ototoxicity, which are common side effects of aminoglycosides.
Side Effects[edit | edit source]
Common side effects of sisomicin include:
Patients receiving sisomicin should be monitored for signs of kidney damage and hearing loss. The risk of these side effects is increased in patients with pre-existing renal impairment or those receiving concurrent nephrotoxic drugs.
Resistance[edit | edit source]
Bacterial resistance to sisomicin can occur through several mechanisms, including:
- Enzymatic modification of the drug by aminoglycoside-modifying enzymes
- Alteration of the ribosomal binding site
- Reduced uptake of the drug into the bacterial cell
Resistance is a significant concern in the clinical use of aminoglycosides, and susceptibility testing is recommended before initiating therapy.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
